Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers March 23, 2019
Pharmacy Choice - Pharmaceutical News - New generic valsartan approved to address shortages - March 23, 2019

Pharmacy News Article

 3/14/19 - New generic valsartan approved to address shortages

The US Food and Drug Administration (FDA) has approved a new generic valsartan to help relieve the recent shortage of the medicine.

The FDA has prioritised the review of this drug application after multiple recalls of generic valsartan products from several manufacturers due to the finding that certain lots of valsartan and other angiotensin II receptor blocker (ARB) medicines contain nitrosamine impurities.

For this approval (Diovan; Alkem Laboratories Ltd), the FDA evaluated the company's manufacturing processes and made sure they used appropriate testing methods to demonstrate that the valsartan product does not contain NDMA or NDEA.

"We know that the ongoing recalls to prevent certain lots of valsartan that contain unacceptable limits of impurities from reaching patients has resulted in a shortage of these important medicines," said FDA Commissioner Scott Gottlieb. "To address the public health consequences of these shortages, we've prioritised the review of generic applications for these valsartan products."

When faced with a drug shortage situation, the FDA employs several strategies to help mitigate the effects of the shortage on patients. As part of that work, the regulator has looked at where they can prioritise review of pending generic applications.

Since last summer, a major investigation into the presence of nitrosamine impurities in certain generic ARB products has been conducted.

Earlier this month, a potential human carcinogen was found in generic angiotensin II receptor blocker (ARB) drug products used to treat high blood pressure and heart failure.

Gottlieb added: "We hope that today's approval of this new generic will help reduce the valsartan shortage, and we remain committed to implementing measures to prevent the formation of these impurities during drug manufacturing processes for existing and future products.

"We'll continue to work with manufacturers so that more medicines like valsartan, that belong to a class of drugs called angiotensin II receptor blockers, can be approved that are free of nitrosamine impurities to continue to address this ongoing shortage."

The post New generic valsartan approved to address shortages appeared first on European Pharmaceutical Review.



© Russell Publishing Limited, 2019. All Rights Reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

LIVE ONLINE CE

Last Chance
Mar 24: A Look Inside the Top 200 Drugs
Mar 25: Medication Use During Pregnancy & Lactation
Mar 26: Nutrigenomics - Nutritional Influences on the Genome
Mar 27: ADHD in Children & Adults: Etiology, Pathology, Pharmacotherapy
Mar 28: Alternatives and Complements to Prescription Pain Management
Click for entire Webinar Calendar

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...

Nursing Jobs
Are you a nurse looking for a job?

Check out the Nursing Job Source.

Your number one choice for nursing jobs.



Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2019 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415